- Previous Close
4.2600 - Open
4.3700 - Bid 4.6600 x 100
- Ask 4.7400 x 100
- Day's Range
4.2500 - 4.7500 - 52 Week Range
4.0900 - 17.2350 - Volume
442,633 - Avg. Volume
387,104 - Market Cap (intraday)
100.049M - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
-- - EPS (TTM)
-4.9500 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.14
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
www.enanta.comRecent News: ENTA
View More
Performance Overview: ENTA
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENTA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENTA
View MoreValuation Measures
Market Cap
100.05M
Enterprise Value
-59.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.49
Price/Book (mrq)
0.89
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-157.57%
Return on Assets (ttm)
-17.75%
Return on Equity (ttm)
-69.10%
Revenue (ttm)
66.59M
Net Income Avi to Common (ttm)
-104.93M
Diluted EPS (ttm)
-4.9500
Balance Sheet and Cash Flow
Total Cash (mrq)
216.69M
Total Debt/Equity (mrq)
197.91%
Levered Free Cash Flow (ttm)
-77.77M
Research Analysis: ENTA
View MoreResearch Reports: ENTA
View MoreDaily – Vickers Top Buyers & Sellers for 02/13/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Lowering target price to $10.00
ENANTA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $10.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about ENTA?
ENANTA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about ENTA?
ENANTA PHARMACEUTICALS INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice Target